{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% Confidence Interval could not be estimated as insufficient number of participants were available for analysis.","groupId":"OG001","lowerLimit":"2.1","upperLimit":"NA","value":"2.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"DOR was defined as the time (in months) from the date of first observation of confirmed response (PR or CR) to the date of the first observation of progression based on the investigator's assessment utilizing RECIST 1.1 for non-HGG cohorts and RANO for HGG cohort, or date of death, whatever the cause. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \\<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent or refractory ewing sarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG000","title":"Phase 2: Cohort 1, Ewing Sarcoma"},{"description":"Participants with recurrent or refractory rhabdomyosarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG001","title":"Phase 2: Cohort 2, Rhabdomyosarcoma"},{"description":"Participants with recurrent or refractory HGG received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG002","title":"Phase 2: Cohort 3, HGG"}],"paramType":"MEDIAN","populationDescription":"Evaluable analysis set included all evaluable participants who have measurable disease present at baseline, and at least one postbaseline efficacy assessment, unless they have discontinued prior to first efficacy assessment due to progressive disease. Here, 'overall number of participants analyzed' signifies participants who had CR or PR.","reportingStatus":"POSTED","timeFrame":"From date of the first observation of CR or PR until the date of first observation of progression or date of death (up to 6.5 months)","title":"Phase 2: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}